GEROPHARM is one of the leaders in the field of biotechnology products in particular in development and production of recombinant human insulin and insulin analogues in Russia. The company is engaged in investing in technological development and setting up of a modern pharmaceutical infrastructure.
Expertise lies mainly within the areas of endocrinology, neurology, psychiatry, ophthalmology, gynecology. The plant capacity of GEROPHARM, certified according to the international quality standards of GMP, is enough to cover 30 % of insulin demand of the Russian Federation. In the near future production facilities of GEROPHARM will fully cover needs of Russian patients and will allow to develop export opportunities.
One of the priorities is development of insulin analogues, which is in line with the goal to strengthen the existing portfolio with advanced products. GEROPHARM is planning to introduce a full pipeline of insulin biosimilars.